FDA Recalls Transderm Scop Scopolamine Transdermal Patches for Temperature Deviation
McKesson Medical-Surgical is recalling Transderm Scop (scopolamine) transdermal patches nationwide due to Good Manufacturing Practice (cGMP) deviations involving temperature abuse during manufacturing. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or adverse events. Temperature abuse during manufacturing is a cGMP deviation affecting a prescription drug product, but without reported harm, this represents a precautionary recall and qualifies as Moderate severity.
Plain-English summary
McKesson Medical-Surgical Inc. is recalling Transderm Scop (scopolamine) 1 mg/3 day transdermal patches nationwide. The recalled product comprises 56 cartons containing 10 patches each, indicated for prevention of motion sickness and post-operative nausea and vomiting (NDC 10019-553-03 and related package codes).
The recall is due to Current Good Manufacturing Practice (cGMP) deviations during manufacturing and distribution, specifically temperature abuse. Temperature exposure could affect the stability and efficacy of the scopolamine within the transdermal patch system. McKesson Medical-Surgical has notified all consignees but is unable to identify specific lot numbers for particular customers.
Healthcare providers and patients with this product should contact their supplier or McKesson Medical-Surgical for guidance. No illnesses or adverse events related to this product have been reported to the FDA. The FDA classifies this as a Class II recall.
The recalled product
- Product
- TRANSDERM SCOP (SCOPOLAMINE)
- Brand
- TRANSDERM SCOP
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Transdermal Patch
- Hazard
- temperature-abuse
- cgmp-deviation
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27